Skip to Content

Posts tagged with "Drug Prices"

  • Cancer

    Again, What’s It Worth to You?

    Let’s open up a painful subject here. This is prompted, partly, by the news the other day about Erbulin. The main reason I posted about that compound was because of its chemical complexity and total-synthesis heritage, both of which are unusual. But it’s an oncology drug. As such, it looks like an awful lot of… Read More
  • "Me Too" Drugs

    Pfizer’s Future: Biotech Followups

    The Wall Street Journal has an article detailing some of Pfizer’s plans in the biologics area: stepping in with second-generation versions of current winners from other companies. New versions of Rituxan and Enbrel are in the works, with the improvements mostly coming in how often the drugs need to be given. They’re not alone in… Read More
  • Business and Markets

    Colchicine’s Price Goes Through the Roof

    We all hear about the new drugs that have just been approved, and we all keep track of the drugs that are coming off patent. But what about the really old ones, the drugs that made it to the market long before today’s regulatory framework? There have long been medicines that are generally recognized as… Read More
  • Business and Markets

    In Which You Get to Hear the Phrase “Hatch-Waxman” Again

    There’s a constant running battle in the drug industry between the two kinds of pharmaceutical companies: the ones who discover the drugs first, and the ones who sell the drugs cheaply after the patents have expired. It surprises me still how many people I run into (outside my work) who don’t make that distinction, or… Read More
  • Drug Industry History

    Fall From Grace

    A couple of articles have come together and gotten me to thinking. Back during the summer, long-time medicinal chemist Mark Murcko published a short editorial in Drug Discovery Today comemmerating the Apollo 11 moon landing’s 40th anniversary: “People like me, who are old enough to actually remember the events of July 1969, are instantl… Read More
  • Business and Markets

    Lexapro, Forest Labs, and the Hard Sell

    Forest Labs has done very, very well with Lexapro (escitalopram) over the years. They’re a comparatively small company, and their collaboration with Lundbeck (also a comparatively small company) in the antidepressant field has been the biggest event in their history. Lexapro is the pure enantiomer of the earlier Lundbeck drug Celexa (citalopr… Read More
  • Current Events

    The PhRMA Deal

    I’m not always a fan of John Boehner, but I think he’s on the right track with his letter to Billy Tauzin (PDF here from NPR’s health care site). I understand that line about how in Washington, if you’re not at the table you’re on the menu. And I understand how the industry wants to… Read More
  • Current Events

    PhRMA’s Negotiating Game

    Now for a bit on the pharma industry and the current fight over health care legislation. Does the industry want a new system to come into force, or not? Depends on what that new system is, of course. But the industry is naturally trying to make sure that it has a hand in whatever passes. Read More
  • Academia (vs. Industry)

    Just Give It to NIH

    I know that many people are getting tired of this topic. But many people who work in the industry have never met someone who’s convinced that drug companies are just standing in the way of innovation, and that all the good stuff comes from the NIH, anyway. So allow me a couple of quick quotes… Read More
  • Current Events

    Health Care Reform – Really?

    I haven’t written about the various health care reform packages that are being hammered out and hammered through the various parts of Congress. That’s partly because I began to think fairly early on in the process that we weren’t actually going to see something happen as quickly as the administration wanted, which meant that there… Read More
...91011...